Company intelligence / Profile preview
ES Therapeutics LLC
New York, New York, United Statesneurology.org ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
ES-481 is currently in Phase II for epilepsy with a 69% phase transition success rate for progressing into Phase III according to GlobalData[4]. The company previously conducted a Phase I trial for ES-481 to evaluate pharmacokinetics, safety, and tolerability after oral administration in healthy volunteers[2].
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Avalo Therapeutics (acquired rights to AVTX-007, AVTX-501, and AVTX-611)[2]
Beyond the preview
Go deeper on ES Therapeutics LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ES Therapeutics LLC.